Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04297280
What this trial is testing

TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Fudan University 25
Testing effectiveness (Phase 2)UnknownNCT04636008
What this trial is testing

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Who this might be right for
Anti-PD-1 AntibodyRadiotherapyRectal Cancer+2 more
West China Hospital 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05605496
What this trial is testing

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies

Who this might be right for
Advanced Solid TumorsMetastatic Solid Tumors
Centre Leon Berard 57
Not applicableUnknownNCT04639284
What this trial is testing

Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

Who this might be right for
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital 200
Early research (Phase 1)UnknownNCT05225116
What this trial is testing

Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Who this might be right for
Hepatocellular Carcinoma
Beijing Tsinghua Chang Gung Hospital 20
Testing effectiveness (Phase 2)UnknownNCT03182816
What this trial is testing

CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor

Who this might be right for
Advanced Solid Tumor
Shanghai Cell Therapy Research Institute 40
Large-scale testing (Phase 3)UnknownNCT05315336
What this trial is testing

L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH

Who this might be right for
Hemophagocytic Lymphohistiocytosis
Beijing Friendship Hospital 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT05531123
What this trial is testing

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

Who this might be right for
Bladder Cancer
Fudan University 30
Testing effectiveness (Phase 2)UnknownNCT06955156
What this trial is testing

Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC

Who this might be right for
Triple Negative Breast Cancer
QIAO LI 50
Early research (Phase 1)Study completedNCT03301688
What this trial is testing

The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001

Who this might be right for
NSCLC
Shanghai Junshi Bioscience Co., Ltd. 38
Early research (Phase 1)UnknownNCT05928962
What this trial is testing

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Who this might be right for
Malignant Melanomas
Fujian Cancer Hospital 10
Testing effectiveness (Phase 2)Study completedNCT03430479
What this trial is testing

Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Kyoto Breast Cancer Research Network 32
Testing effectiveness (Phase 2)Looking for participantsNCT07183865
What this trial is testing

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Who this might be right for
Locally Recurrent Rectal Cancer
Fudan University 44
Testing effectiveness (Phase 2)Looking for participantsNCT07387198
What this trial is testing

Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab

Who this might be right for
Merkel Cell Carcinoma, Stage IMerkel Cell Carcinoma, Stage IINeoadjuvant Immunotherapy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 135
Not applicableActive Not RecruitingNCT04612309
What this trial is testing

Retrospective Study on the Use of Immunotherapy in Patients With MSI-H Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Gruppo Oncologico Italiano di Ricerca Clinica 100
Large-scale testing (Phase 3)Looking for participantsNCT06749899
What this trial is testing

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Who this might be right for
Nasopharyngeal Cancinoma (NPC)Nasopharyngeal Cancer
Sun Yat-Sen University Cancer Center 580
Testing effectiveness (Phase 2)Looking for participantsNCT06868836
What this trial is testing

Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd. 78
Testing effectiveness (Phase 2)UnknownNCT05522894
What this trial is testing

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

Who this might be right for
Unresectable Esophageal Squamous Cell CarcinomaLocally Advanced Esophageal Squamous Cell CarcinomaMetastatic Esophageal Squamous Cell Carcinoma
Chinese Academy of Medical Sciences 80
Testing effectiveness (Phase 2)Study completedNCT03977272
What this trial is testing

Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Zhejiang University 110
Testing effectiveness (Phase 2)Looking for participantsNCT05512351
What this trial is testing

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma

Who this might be right for
Oligodendroglioma
Henan Provincial People's Hospital 80
Next Page